Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Veranderingen in velocimetrische indices van baarmoeder- en navelstrengslagaders voor en na gecombineerde spinale-epidurale analgesie bij barende vrouwen (DEEL II)

Veranderingen in velocimetrische indices van baarmoeder- en navelstrengslagaders voor en na gecombineerde spinale-epidurale analgesie bij barende vrouwen (DEEL I en DEEL II)

Combined spinal-epidural (CSE) for labor analgesia has been used for many years and is practiced commonly at our institution, especially when the patient requests immediate pain relief. CSE is not only beneficial for its faster onset of analgesia, but also it is favorable in relation to the need for rescue analgesia, urinary retention, and rate of instrumental delivery compared to the traditional epidural. Despite its beneficial effects, there is a risk of about 15-30% of developing abnormal fetal heart rate following CSE. This is self-resolving with minimal or no intervention. Although the cause of fetal bradycardia is not fully elucidated, variations in uterine artery blood flow after epidural analgesia are thought to be due to the interaction of numerous events related to blockade of sympathetic innervations, fluid administration, maternal hypotension, uterine vascular effects of sympathetic block, fluctuations in circulating catecholamines, and possibly the effect of opioids. Similar mechanism is thought to be a cause of fetal bradycardia after the CSE with its faster onset and superior block.

Maternal or fetal circulation during labor can be assessed using continuous-wave Doppler ultrasound to monitor maternal uterine artery (UtA) and fetal umbilical artery (UmA) velocity waveforms to detect changes in blood flow. The velocimetry indices mentioned above have been often used to assess the changes in the blood flow before and after the induction of epidural analgesia during labor in several studies. Although there are some studies regarding the effect of labor epidural analgesia using velocimetry indices, but there is currently no published study evaluating velocimetry indices of uterine and umbilical arteries before and after the induction of CSE. Thus, the aim of this study is to investigate the impact of CSE to maternal and fetal blood flow to evaluate the relationships.

The investigators hypothesize that both uterine artery and umbilical artery blood flow are reduced after the induction of CSE, which may be responsible for the occurrence of fetal bradycardia.

Studie Overzicht

Toestand

Werving

Conditie

Interventie / Behandeling

Studietype

Ingrijpend

Inschrijving (Geschat)

54

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • Ontario
      • Toronto, Ontario, Canada, M5G1X5
        • Werving
        • Mount Sinai Hospital
        • Onderonderzoeker:
          • Cristian Arzola, MD
        • Onderonderzoeker:
          • Sebastian Hobson, MD
        • Onderonderzoeker:
          • Kristi Downey, MSc
        • Contact:
        • Onderonderzoeker:
          • Javiera Vargas Zuniga, MD
        • Onderonderzoeker:
          • Fernanda Lanza Oliveira, MD
        • Onderonderzoeker:
          • Claudia Jimenez, MD
        • Onderonderzoeker:
          • Amir Siddiqui, MD

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 50 jaar (Volwassen)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Vrouw

Beschrijving

Inclusion Criteria:

  • Written informed consent
  • Term pregnant patients requesting labor analgesia
  • Singleton pregnancy
  • Term pregnant patients in active labor
  • ASA<4
  • No evidence of fetal congenital anomalies, fetal compromise or fetal decelerations prior to CSE
  • Patients with and without diagnosed hypertensive disorders of pregnancy

Exclusion Criteria:

  • Refusal to consent for the study
  • Known spinal deformities
  • Previous back instrumentation
  • Patients with BMI>50 kg/㎡ due to anticipated technical challenges in Doppler studies

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Diagnostisch
  • Toewijzing: Niet-gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Ultrasound - patients without hypertensive disorders of pregnancy

Ultrasound will be used to measure velocimetric index of the umbilical artery.

Ultrasound scan of the umbilical artery

Experimenteel: Ultrasound - patients with diagnosed hypertensive disorders of pregnancy

Ultrasound will be used to measure velocimetric index of the umbilical artery.

Ultrasound scan of the umbilical artery

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Umbilical artery velocimetric index - systolic/diastolic ratio (S/D) at 10 minutes
Tijdsspanne: 10 minutes

Umbilical artery velocimetric index - systolic/diastolic ratio (S/D) will be measured 10 minutes after combined spinal epidural, with the uterus in relaxed and contracted states.

10 minutes
Umbilical artery velocimetric index - pulsatility index (PI) at 10 minutes
Tijdsspanne: 10 minutes

Umbilical artery velocimetric index - pulsatility index (PI) will be measured 10 minutes after combined spinal epidural, with the uterus in relaxed and contracted states.

10 minutes
Umbilical artery velocimetric index - resistance index (RI) at 10 minutes
Tijdsspanne: 10 minutes

Umbilical artery velocimetric index - resistance index (RI) will be measured 10 minutes after combined spinal epidural, with the uterus in relaxed and contracted states.

10 minutes

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Umbilical artery velocimetric index - systolic/diastolic ratio (S/D) at baseline
Tijdsspanne: 5 minutes

Umbilical artery velocimetric index - systolic/diastolic ratio (S/D) will be measured prior to combined spinal epidural, with the uterus in relaxed and contracted states.

5 minutes
Umbilical artery velocimetric index - pulsatility index (PI) at baseline
Tijdsspanne: 5 minutes

Umbilical artery velocimetric index - pulsatility index (PI) will be measured prior to combined spinal epidural, with the uterus in relaxed and contracted states.

5 minutes
Umbilical artery velocimetric index - resistance index (RI) at baseline
Tijdsspanne: 5 minutes

Umbilical artery velocimetric index - resistance index (RI) will be measured prior to combined spinal epidural, with the uterus in relaxed and contracted states.

5 minutes
Umbilical artery velocimetric index - systolic/diastolic ratio (S/D) at 5 minutes
Tijdsspanne: 5 minutes

Umbilical artery velocimetric index - systolic/diastolic ratio (S/D) will be measured 5 minutes after combined spinal epidural, with the uterus in relaxed and contracted states.

5 minutes
Umbilical artery velocimetric index - pulsatility index (PI) at 5 minutes
Tijdsspanne: 5 minutes

Umbilical artery velocimetric index - pulsatility index (PI)will be measured 5 minutes after combined spinal epidural, with the uterus in relaxed and contracted states.

5 minutes
Umbilical artery velocimetric index - resistance index (RI) at 5 minutes
Tijdsspanne: 5 minutes

Umbilical artery velocimetric index - resistance index (RI) will be measured 5 minutes after combined spinal epidural, with the uterus in relaxed and contracted states.

5 minutes
Umbilical artery velocimetric index - systolic/diastolic ratio (S/D) at 20 minutes
Tijdsspanne: 20 minutes

Umbilical artery velocimetric index - systolic/diastolic ratio (S/D) will be measured 20 minutes after combined spinal epidural, with the uterus in relaxed and contracted states.

20 minutes
Umbilical artery velocimetric index - pulsatility index (PI) at 20 minutes
Tijdsspanne: 20 minutes

Umbilical artery velocimetric index - pulsatility index (PI) will be measured 20 minutes after combined spinal epidural, with the uterus in relaxed and contracted states.

20 minutes
Umbilical artery velocimetric index - resistance index (RI) at 20 minutes
Tijdsspanne: 20 minutes

Umbilical artery velocimetric index - resistance index (RI) will be measured 20 minutes after combined spinal epidural, with the uterus in relaxed and contracted states.

20 minutes
Umbilical artery velocimetric index - systolic/diastolic ratio (S/D) at 30 minutes
Tijdsspanne: 5 minutes

Umbilical artery velocimetric index - systolic/diastolic ratio (S/D) will be measured 30 minutes after combined spinal epidural, with the uterus in relaxed and contracted states.

5 minutes
Umbilical artery velocimetric index - pulsatility index (PI) at 30 minutes
Tijdsspanne: 30 minutes

Umbilical artery velocimetric index - pulsatility index (PI) will be measured 30 minutes after combined spinal epidural, with the uterus in relaxed and contracted states.

30 minutes
Umbilical artery velocimetric index - resistance index (RI) at 30 minutes
Tijdsspanne: 30 minutes

Umbilical artery velocimetric index - resistance index (RI) will be measured 30 minutes after combined spinal epidural, with the uterus in relaxed and contracted states.

30 minutes
Pain score at baseline - questionnaire
Tijdsspanne: 1 minute

Pain score - verbal numeric rating scale (0-10) prior to combined spinal epidural

1 minute
Pain score at 10 minutes - questionnaire
Tijdsspanne: 10 minutes

Pain score - verbal numeric rating scale (0-10) at 10 minute after combined spinal epidural

10 minutes
Pain score at 30 minutes - questionnaire
Tijdsspanne: 30 minutes

Pain score - verbal numeric rating scale (0-10) at 30 minute3 after combined spinal epidural

30 minutes
Sensory block level at 10 minutes
Tijdsspanne: 10 minutes

Sensory block level at 10 minutes following combined spinal epidural

10 minutes
Sensory block level at 30 minutes
Tijdsspanne: 30 minutes

Sensory block level at 30 minutes following combined spinal epidural

30 minutes
frequency of uterine contractions
Tijdsspanne: 10 minutes

The number of contractions on the monitor in a 10 minute period.

10 minutes
Presence of prolonged hypertonic uterine contractions- questionnaire
Tijdsspanne: 30 minutes

Presence of prolonged hypertonic uterine contractions as measured by the monitor

30 minutes
Hypotension: systolic blood pressure less than 80% of baseline
Tijdsspanne: 30 minutes

Systolic blood pressure < 80% of baseline, monitored q5 for 30 minutes following combined spinal epidural

30 minutes
Hypertension: systolic blood pressure greater than 120% of baseline
Tijdsspanne: 30 minutes

Systolic blood pressure > 120% of baseline, monitored q5 for 30 minutes following combined spinal epidural

30 minutes
Bradycardia: heart rate less than 70% of baseline
Tijdsspanne: 30 minutes

Heart rate < 70% of baseline or a heart rate < 50bpm, monitored q5 for 30 minutes following combined spinal epidural

30 minutes
Desaturation: oxygen level <95%
Tijdsspanne: 30 minutes

Oxygen level <95%, monitored q5 for 30 minutes following combined spinal epidural

30 minutes
fetal heart rate at baseline
Tijdsspanne: 5 minutes

fetal heart rate at baseline, prior to combined spinal epidural

5 minutes
fetal heart rate q5 min up to 30 minutes
Tijdsspanne: 30 minutes

fetal heart rate q5 min up to 30 minutes following combined spinal epidural

30 minutes
presence of fetal bradycardia - questionnaire
Tijdsspanne: 30 minutes

presence of fetal bradycardia (fetal heart rate <110)

30 minutes
presence of fetal prolonged deceleration - questionnaire
Tijdsspanne: 30 minutes

presence of fetal prolonged deceleration (fetal heart rate <110/min lasting less than 10 minutes)

30 minutes
presence of fetal persistent late decelerations - questionnaire
Tijdsspanne: 30 minutes

presence of fetal persistent late decelerations will be recorded

30 minutes
presence of fetal non-reassuring variable deceleration - questionnaire
Tijdsspanne: 30 minutes

presence of fetal non-reassuring variable deceleration will be recorded

30 minutes
presence of fetal salutatory variability - questionnaire
Tijdsspanne: 30 minutes

presence of fetal salutatory variability (FHR change>25beats) will be recorded

30 minutes
Neonatal weight
Tijdsspanne: up to 24 hours

Neonatal weight measured after delivery in grams minutes

up to 24 hours
Apgar score at 1 minute
Tijdsspanne: 1 minute

Apgar score at 1 minute

1 minute
Apgar score at 5 minutes
Tijdsspanne: 5 minutes

Apgar score at 5 minutes

5 minutes
Mode of delivery - questionnaire
Tijdsspanne: up to 24 hours

Mode of delivery will be recorded as vaginal, assisted (forceps or vacuum), or cesarean

up to 24 hours

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Mrinalini Balki, MD, MOUNT SINAI HOSPITAL

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

30 oktober 2024

Primaire voltooiing (Geschat)

1 december 2027

Studie voltooiing (Geschat)

1 december 2027

Studieregistratiedata

Eerst ingediend

17 oktober 2024

Eerst ingediend dat voldeed aan de QC-criteria

22 oktober 2024

Eerst geplaatst (Werkelijk)

23 oktober 2024

Updates van studierecords

Laatste update geplaatst (Werkelijk)

16 november 2026

Laatste update ingediend die voldeed aan QC-criteria

12 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren